Invivyd, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IVVD research report →
Companyadagiotx.com
Adagio Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease.
- CEO
- William E. Duke Jr.
- IPO
- 2021
- Employees
- 99
- HQ
- Waltham, MA, US
Price Chart
Valuation
- Market Cap
- $144.68M
- P/E
- -4.35
- P/S
- 2.59
- P/B
- 1.66
- EV/EBITDA
- 0.39
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 92.02%
- Op Margin
- -146.38%
- Net Margin
- -138.90%
- ROE
- -53.48%
- ROIC
- -38.63%
Growth & Income
- Revenue
- $53.43M · 110.47%
- Net Income
- $-52,489,000 · 69.11%
- EPS
- $-0.30 · 79.02%
- Op Income
- $-55,560,000
- FCF YoY
- 65.84%
Performance & Tape
- 52W High
- $3.07
- 52W Low
- $0.48
- 50D MA
- $1.49
- 200D MA
- $1.67
- Beta
- 0.71
- Avg Volume
- 2.96M
Get TickerSpark's AI analysis on IVVD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 15, 26 | Allen Robert D. III | other | 99,000 |
| Feb 17, 26 | Allen Robert D. III | sell | 18,189 |
| Feb 18, 26 | Allen Robert D. III | sell | 19,392 |
| Feb 15, 26 | Allen Robert D. III | other | 99,000 |
| Feb 15, 26 | Green Julie | other | 99,000 |
| Feb 17, 26 | Green Julie | sell | 19,663 |
| Feb 18, 26 | Green Julie | sell | 20,964 |
| Feb 15, 26 | Green Julie | other | 99,000 |
| Feb 15, 26 | Duke William E. | other | 99,000 |
| Feb 17, 26 | Duke William E. | sell | 19,663 |
Our IVVD Coverage
We haven't published any research on IVVD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IVVD Report →